Download PDF
Nervenheilkunde 2006; 25(04): 264-270
DOI: 10.1055/s-0038-1626464
Originaler Artikel
Schattauer GmbH

Aktueller Stand bei toxischen Myopathien

Update on toxic myopathies
V. Fürer
1   Klinik und Poliklinik für Neurologie, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden
,
H. Reichmann
1   Klinik und Poliklinik für Neurologie, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden
› Author Affiliations
Further Information

Publication History

Publication Date:
19 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Eine zunehmende Anzahl von Medikamenten und Toxinen kann zu funktionellen und strukturellen Veränderungen der Skelettmuskulatur führen. Das klinische Bild reicht von einer asymptomatischen CK-Erhöhung über Muskelschmerzen und -paresen bis zur potenziell tödlichen Rhabdomyolyse. Das frühe Erkennen dieser Myopathien ist für den Krankheitsverlauf entscheidend, da sie nach Absetzen des auslösenden Agens meist reversibel sind. Ihre pathophysiologischen Hintergründe sind vielfach noch ungeklärt. Die häufigste Toxin-induzierte Myopathie ist die Alkoholmyopathie. Unter den medikamentös-induzierten Myopathien finden vor allem die Lipidsenker-, daneben auch die Steroidmyopathien Beachtung. Zunehmend an Bedeutung haben die in der antiretroviralen HIV-Therapie eingesetzten Substanzen in den letzten Jahren gewonnen.

Summary

A growing number of drugs and toxins can cause functional and structural damage to human skeletal muscle. These myopathies may manifest themselves as an asymptomatic creatinin kinase elevation, muscle pain or weakness and even acute rhabdomyolysis. Early diagnosis is important, because these myopathies are potentially reversible on removal of the offending agent. The precise mechanisms remain mostly unclear. Main source ofa toxic myopathy is chronic alcohol abuse. Drug-induced myopathies are most frequently seen due to lipid lowering agents and corticosteroids. Since introduction of specific HIV-therapy antiretroviral substances gain importance as another trigger for myopathy.

Schlüsselwörter

Myopathie - Mechanismen - Alkohol - Kortikosteroide - Lipidsenker - antiretrovirale Therapie

Keywords

Myopathy - mechanisms - alcohol - corticosteroids - lipid lowering agents - antiretroviral therapy
 

  • Literatur

  • 1 Amaya-Villar R. et al. Steroid-induced myopathy in patients intubated due to exacerbation of chronic obstructive pulmonary disease. Intensive Care Med 2005; 31: 157-61.
    CrossrefPubMedGoogle Scholar
  • 2 Arzneimittelkommission der deutschen Ärzteschaft. Aus der UAW-Datenbank. Myopathien bzw. Leberreaktionen unter Ezetimib (Ezetrol®). Dtsch Ärztebl 2004; 101: A959.
    Google Scholar
  • 3 Authier FJ. et al. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 2005; 32: 247-60.
    CrossrefPubMedGoogle Scholar
  • 4 Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 2001; 24: 258-72.
    PubMedGoogle Scholar
  • 5 Batchelor TT, Taylor LP, Thaler HAT. et al. Steroid myopathy in cancer patients. Neurology 1997; 48: 1234-8.
    CrossrefPubMedGoogle Scholar
  • 6 Campellone JV. et al. Acute myopathy after liver transplantation. Neurology 1998; 50: 46-53.
    PubMedGoogle Scholar
  • 7 Chariot P, Bignani O. Skeletal muscle disorders associated with selenium deficiency in humans. Muscle Nerve 2003; 27: 662-8.
    CrossrefPubMedGoogle Scholar
  • 8 Chariot P, Dubreuil-Lemaire ML. et al. Muscle involvement in human immunodeficiency virusinfected patients is associated with marked selenium deficiency. Muscle Nerve 2003; 27: 662-8.
    CrossrefPubMedGoogle Scholar
  • 9 Chariot P. et al. Blood lactate/ pyruvate ratio as a non invasive test for the diagnosis of zidovudine myoopathy. Arthritis Rheum 1994; 37: 583-6.
    CrossrefPubMedGoogle Scholar
  • 10 Deconick N. et al. Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents. Neuromuscul Disord 1998; 08: 186-92.
    CrossrefPubMedGoogle Scholar
  • 11 De Pinieux G. et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996; 42: 333-7.
    PubMedGoogle Scholar
  • 12 Faludi G, Gotlieb J, Meyers J. Factors influencing the development of steroid-induced myopathies. Ann NY Acad Sci 1966; 138: 62-72.
    PubMedGoogle Scholar
  • 13 Fernandez-Sola J. et al. Patients with chronic glucocorticoid treatment develop changes in muscle glykogen metabolism. J Neurol Sci 1993; 117: 103-6.
    CrossrefPubMedGoogle Scholar
  • 14 Fernandez-Sola J. et al. Low-dose ethanol consumption allows strength recovery in chronic alcoholic myopathy. QJ Med 2000; 93: 35-40.
    CrossrefPubMedGoogle Scholar
  • 15 Finsterer J, Hess B, Jarius C. et al. Malnutritioninduced hypokalemic myopathy in chronic alcoholism. J Toxicol Clin Toxicol 1998; 36: 369-73.
    CrossrefPubMedGoogle Scholar
  • 16 Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthesis inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1997; 145: 91-8.
    CrossrefPubMedGoogle Scholar
  • 17 Fux R. et al. Ezetimibe and statin-associated myopathy. Ann Intern Med 2004; 140: 671-2.
    CrossrefPubMedGoogle Scholar
  • 18 Gayan-Ramirez G. et al. Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. Am J Respir Crit Care Med 1999; 159: 283-9.
    CrossrefPubMedGoogle Scholar
  • 19 Guis S, Mattei JP, Liote F. Drug-induced and toxic myopathies. Best Pract Res Clin Rheumatol 2003; 17 (06) 877-907.
    CrossrefPubMedGoogle Scholar
  • 20 Gutmann L, Blumenthal D, Schochet SS. Acute type II myofiber atrophy in critical illness. Neurology 1996; 46: 819-21.
    CrossrefPubMedGoogle Scholar
  • 21 Haller RG, Carter NW, Ferguson E, Knochel JP. Serum and muscle potassium in experimental alcoholic myopathy. Neurology 1984; 34: 529-32.
    CrossrefPubMedGoogle Scholar
  • 22 Hickson RC, Czerwinski SM, Wegrzyn LE. Glutamine prevents downregulation of myosin heavy chain synthesis and muscle atrophy from glucocorticoids. Am J Physiol 1995; 268: E730-4.
    Google Scholar
  • 23 Hirano M, Ott BR, Raps EC. et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1999; 42: 2082-7.
    Google Scholar
  • 24 Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 10; 128: 159-68.
    Google Scholar
  • 25 Kagan T, Davis C, Lin L, Zakeri Z. Coenzyme Q 10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria. Ann NY Acad Sci 1999; 887: 31-47.
    CrossrefPubMedGoogle Scholar
  • 26 Kanda F, Okuda S, Matsushita T. et al. Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res 2001; 56: 24-8.
    CrossrefPubMedGoogle Scholar
  • 27 Lindner A, Zierz S. Rhabdomyolyse und Myoglobinurie. Nervenarzt 2003; 74: 505-515.
    CrossrefPubMedGoogle Scholar
  • 28 MacFarlane IA, Rosenthal FD. Severe myopathy after status asthmaticus. Lancet 1977; 02: 615.
    Google Scholar
  • 29 Menge T, von Büdingen HC. et al. Statine zur Behandlung von Erkrankungen des zentralen Nervensystems. Nervenarzt 2005; 76: 426-37.
    CrossrefPubMedGoogle Scholar
  • 30 Neuhaus O, Wiendl H, Kieseier BC. et al. Cholesterinsenkereine neue Therapieoption bei Multipler Sklerose?. Nervenarzt 2003; 74: 704-8.
    CrossrefPubMedGoogle Scholar
  • 31 Niemela O. et al. Generation of aldehyde-derived protein modifications in ethanol-exposed heart. Alcohol Clin Exp Res 2003; 27: 1987-91.
    CrossrefPubMedGoogle Scholar
  • 32 Owczarek J, Jasinska M. et al. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Reports 2005; 57: 23-34.
    Google Scholar
  • 33 Pasternak RC, Smith SC. et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 568-73.
    Google Scholar
  • 34 Phillips PS, Haas RH, Bannykh S. et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 13: 581-5.
    Google Scholar
  • 35 Reimertz C. Herz-und Skelettmuskelveränderungen bei HIV: Zusammenfassung der bisherigen Ergebnisse. Infektionsepidemiologische Forschung (Robert-Koch-Insitut) 1997; 03: 7-50.
    Google Scholar
  • 36 Richmann D. et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebocontrolled trial. N Engl J Med 1987; 317: 192-7.
    PubMedGoogle Scholar
  • 37 Rieckmann P, Kallmann B. Neue Therapieansätze bei Multipler Sklerose. Nervenheilkunde 2005; 24: 294-300.
    Article in Thieme ConnectGoogle Scholar
  • 38 Sieb J, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve 2003; 27: 142-56.
    CrossrefPubMedGoogle Scholar
  • 39 Singleton JR, Baker BL, Thorburn A. Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis. Endocrinology 2000; 141: 2945-50.
    CrossrefPubMedGoogle Scholar
  • 40 Sitwell LD, Weinshenker BG, Monpetit V, Reid D. Complete opthalmoplegia as a complication of acute corticosteroidand pancuronium associated myopathy. Neurology 1991; 41: 921-2.
    CrossrefPubMedGoogle Scholar
  • 41 Slavin G, Martin F. et al. Chronic alcohol excess is associated with selective but reversible injury to 2B muscle fibers. J Clin Pathol 1983; 36: 722-77.
    PubMedGoogle Scholar
  • 42 Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-90.
    CrossrefPubMedGoogle Scholar
  • 43 Urbano-Marquez A, Fernandez-Sola J. Effects of alcohol on skeletal and cardiac muscle. Muscle Nerve 2004; 30: 689-707.
    CrossrefPubMedGoogle Scholar
  • 44 Wortmann RL. Lipid-lowering agents and myopathy. Curr Opin Rheumatol 2002; 14: 643-7.
    CrossrefPubMedGoogle Scholar